ITP showdown: daily pill vs IV infusion in major new trial
NCT ID NCT07051915
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial will compare two second-line treatments for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risk. About 220 adults who didn't respond to steroids will be randomly assigned to take avatrombopag (a daily pill that boosts platelet production) or rituximab (an IV infusion that targets immune cells). The main goal is to see which treatment leads to more stable platelet counts over 28 weeks, with follow-up on quality of life and fatigue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Avatrombopag (daily pill) or Rituximab (IV infusion)
What this could lead to
If successful, this could show which second-line treatment works better for ITP patients who didn't respond to steroids, potentially improving platelet counts and quality of life.
What could go wrong
This is a phase 3 trial, but it's not yet recruiting. Results may not apply to all ITP patients, and both drugs have side effects like infection risk (rituximab) or liver issues (avatrombopag).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.